問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F.

Recruiting

List

554Cases

2021-04-01 - 2024-05-14

Phase II

-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
4Sites

Recruiting4Sites

2021-04-09 - 2024-12-31

Phase II

-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Recruiting6Sites

2021-11-01 - 2022-08-29

Phase III

-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Recruiting6Sites

2023-10-10 - 2027-07-14

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Recruiting5Sites

2024-01-01 - 2027-12-31

Phase III

Active
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

  • Condition/Disease

    Moderate to Severe Plaque Psoriasis

  • Test Drug

    N/A

Participate Sites
7Sites

Recruiting7Sites

2021-11-15 - 2023-12-30

Phase III

xxxxxx

  • Condition/Disease

    xxxxxx

  • Test Drug

    Ibuprofen Modified-Release Tablets 800 mg

Participate Sites
9Sites

Recruiting9Sites

2020-09-01 - 2022-08-31

Others

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2016-03-15 - 2018-03-15

Phase III

A Phase III Trial to Compare the Safety and Efficacy of Intravenous UB-851 and Eprex® With an Extension Safety Evaluation in Subjects With Renal Anemia on Hemodialysis

  • Condition/Disease

    Renal Anemia

  • Test Drug

    UB-851

Participate Sites
18Sites

Recruiting10Sites

Terminated8Sites

唐德成
Taipei Veterans General Hospital

Division of Nephrology

2019-04-01 - 2020-04-01

Phase I

A Phase I, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of UB-221 as an Add-on Therapy in Patients With Chronic Spontaneous Urticaria

  • Condition/Disease

    Chronic Spontaneous Urticaria

  • Test Drug

    UB-221

Participate Sites
2Sites

Recruiting2Sites

2019-01-23 - 2022-12-30

Phase III

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Oral BTK Inhibitor PRN1008 in Moderate to Severe Pemphigus

  • Condition/Disease

    Pemphigus

  • Test Drug

    PRN1008

Participate Sites
3Sites

Recruiting3Sites

1 47 48 49 50 51 56
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB